Dr. Steven R. Goldstein MD- Gynecologist New York, NYC Gyn

Dr Steven R. Goldstein MD is a top Gynecologist in New York. Dr Goldstein’s clinical research has had a significant influence on the way gynecology is practiced.

In 1991, he was the first to suggest that a thin, distinct endometrial echo on transvaginal ultrasound in postmenopausal bleeding did not indicate the need for a biopsy. This was finally adopted as the standard of care by the American Congress of Obstetricians and Gynecologists (ACOG) in 2009.

As a top rated NYC Gyn, In 1989, he was the first to suggest that simple cysts of postmenopausal ovaries were benign and did not require surgical intervention. In 2009 that, too, became the standard of care.

In 1994, he first described endometrial fluid collections on vaginal sonograms as a naturally occurring, de facto sonohysterogram and determined that when tissue surrounding the fluid is thin, endometrial disease can be excluded.

Also in 1994, he was the first to describe the glandular cystic atrophy causing an unusual ultrasound appearance in women receiving tamoxifen, and has since been involved in the study of — and has published research on — practically every selective estrogen-receptor modulator, including raloxifene, lasofoxifene, levormeloxifene, arzoxifene, and ospemifene.

Dr. Goldstein, a top NYC Gyn, was the first, in 2004, to warn against unnecessary biopsy in nonbleeding postmenopausal patients with an incidental finding of thick endometrial lining on vaginal sonogram, which was affirmed by ACOG in its Practice Bulletin in 2009, and reaffirmed in 2015.

Since 1995, Dr. Goldstein has argued against blind endometrial biopsies. He also championed saline infusion sonohysterogram — which was finally endorsed by ACOG in its Practice Bulletin in 2012.

For a consultation with this top Gynecologist in New York, visit Dr Goldstein’s website at www.goldsteinmd.com for more information or to make an appointment